Myomo Inc. Reports Fourth‑Quarter 2025 Results
Date: 9 March 2026Source: Benzinga, Seeking Alpha, Finanzen.net, Seeking Alpha
1. Earnings Highlights
Myomo Inc. released its fiscal fourth‑quarter 2025 financial results on 9 March 2026. The company reported a non‑GAAP earnings per share (EPS) of ‑$0.37, falling short of analyst expectations by $0.28. This figure contrasts with the previous year‑ago quarter, which saw a non‑GAAP EPS of ‑$0.01.
Revenue for the quarter reached $11.4 million, surpassing the consensus estimate of $10.4 million and beating the previous year‑ago figure of $12.1 million by $1 million. The revenue growth represents a 13.84 % decline relative to the 12‑month period ending March 2024, yet it still exceeded market expectations.
2. Analyst Forecasts
Five analysts covering Myomo projected an average EPS loss of ‑$0.086 for the fourth quarter, implying a 760 % decline versus the prior year‑ago quarter. They also expected quarterly sales of $10.4 million. At the close of the fiscal year, consensus estimates anticipated a year‑end loss per share of ‑$0.366, compared to ‑$0.160 in the previous fiscal year, and projected annual revenue of $40 million, up from $32.6 million in the prior year.
3. Company Context
Myomo Inc. is a medical‑robotics firm headquartered in Cambridge, Massachusetts, that develops and markets powered arm‑brace systems for individuals with neurological disorders or upper‑limb paralysis. The company trades on the New York Stock Exchange (ticker: MYO) and reported a market capitalization of $30.8 million as of the close price of $0.801 on 5 March 2026. Its 52‑week high and low were $6.30 and $0.641, respectively. The company’s price‑to‑earnings ratio is ‑2.91, reflecting its ongoing operating losses.
4. Financial Summary
| Metric | Q4 2025 | YoY Change | Analyst Consensus |
|---|---|---|---|
| Non‑GAAP EPS | ‑$0.37 | −370 % | ‑$0.086 |
| Revenue | $11.4 M | −13.8 % | $10.4 M |
| Full‑Year EPS | ‑$0.366 | −? | ‑$0.366 |
| Full‑Year Revenue | $40 M | +? | $40 M |
(Percentages reflect changes from the same quarter in the preceding year.)
5. Outlook
The company’s earnings miss and the projected negative full‑year EPS suggest continued operational challenges. However, the revenue beat indicates some resilience in sales of its arm‑brace products. Market participants will likely focus on future guidance, cost‑management initiatives, and any progress in clinical trials or regulatory approvals that could impact the company’s long‑term prospects.
